
Opinion|Videos|January 10, 2025
Assessing New Therapies for Retinal Diseases
Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- New Therapies:
- Aflibercept 8 mg
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves subcutaneous Enspryng for TED
2
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
3
OT Roundup: Optogenetics Nobel Prize, BRUNELLO, DRAGON, eye transplant
4
EC-104 outperforms Ozurdex in phase 2 BETTIS-1 trial for anti-VEGF–resistant DME
5


















